Seattle’s life sciences market is “stable” despite a drop in federal funding last year
Seattle’s life sciences market remains stable despite declines in federal and venture funding, according to Colliers’ 2026 outlook report.
The report highlights continued leasing activity in 2025, including major commitments from SystImmune and Seattle Children’s Research Institute, alongside the delivery of more than 500,000 square feet of new lab space with moderate pre-leasing. At the same time, vacancy rose to 22.8% and funding softened, with NIH grants in Washington falling 2.6% and venture capital activity producing only three deals above $100 million, all in the first half of the year. Despite these headwinds, Seattle ranked No. 7 nationally across key life sciences market indicators.
The region’s ability to maintain stability amid shifting funding dynamics underscores the resilience of its life sciences ecosystem and its capacity for long-term growth.